Clinical Trials Logo

Silent Cerebral Infarct clinical trials

View clinical trials related to Silent Cerebral Infarct.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05685069 Recruiting - Silent Stroke Clinical Trials

Prevalence of Attributable Etiology and Modifiable Stroke Risk Factors in Patients With Covert Brain Infarctions

CBI-Registry
Start date: March 1, 2019
Phase:
Study type: Observational

The CBI registry is a prospective, interdisciplinary, multimodal observational registry of patients with covert brain infarction. Methods: A standardized workup in analogy to manifest ischemic stroke including cerebral MRI, long-term rhythm monitoring (3 x 7 days ECG), echocardiography, laboratory work-up and risk factor assessment as well as noninvasive angiography of the cervical and intracranial arteries will be performed.

NCT ID: NCT05146037 Recruiting - Stroke Clinical Trials

INTERvention With Cerebral Embolic Protection in Transcatheter Aortic Valve Implantation (INTERCEPTavi)

INTERCEPTavi
Start date: September 1, 2021
Phase: N/A
Study type: Interventional

The study aims to evaluate the processes of a pilot single-centre randomised controlled trial (RCT) of carbon-dioxide flushing of transcatheter aortic valves (TAVI-CO2) versus standard saline flushing of valves (TAVI-S) and assess potential neuroprotection through a number of neurological endpoints for planning of a full-sized RCT

NCT ID: NCT04449523 Recruiting - Silent Stroke Clinical Trials

Incidence of Silent Atrial Fibrillation in Patients With Clinically Silent Brain Ischemic Lesions

SILENT2
Start date: September 8, 2020
Phase:
Study type: Observational

Arterial Fibrillation (AF) is well-recognized as a cause for cryptogenic Acute Ischemic Stroke (AIS) and is associated with Silent Brain Infarction (SBI). However, the role of AF in the formation of lesions (SBIs) is less well established than its role in AIS and needs clarification. The investigators hypothesize that continuous rhythm monitoring will yield a similar incidence of AF diagnosis in patients with SBI as compared to patients with cryptogenic AIS. The primary objective is to assess the cumulative incidence of AF diagnosis at 24 months in patients with SBI.